Today: 23 May 2026
Browse Category

NYSE:LLY 10 November 2025 - 30 November 2025

Eli Lilly (LLY) Stock Outlook Before Market Open on December 1, 2025: Trillion‑Dollar Rally Pauses After Policy Shock

Eli Lilly (LLY) Stock Outlook Before Market Open on December 1, 2025: Trillion‑Dollar Rally Pauses After Policy Shock

Eli Lilly shares closed at $1,075.47 on Friday, down 2.6% after a month-long rally that briefly pushed its market value above $1 trillion. The stock remains up about 39% year-to-date and surged roughly 26–31% in November, driven by demand for its obesity drugs. Investors are weighing recent policy headlines and valuation concerns ahead of Monday’s open. No pre-market quote was available with US markets closed over the weekend.
Eli Lilly Stock on November 30, 2025: Trillion‑Dollar Pharma, GLP‑1 Boom and Valuation Jitters Around LLY

Eli Lilly Stock on November 30, 2025: Trillion‑Dollar Pharma, GLP‑1 Boom and Valuation Jitters Around LLY

Eli Lilly closed Friday at $1,075 per share, capping a November surge that pushed its market value above $1 trillion—the first for a pharmaceutical company. Shares rose about 26% in November and are up over 40% in 2025. Investors are debating whether the stock, trading at a trailing P/E of 70, can sustain further gains amid strong demand for its GLP-1 obesity drugs.
Eli Lilly (LLY) Stock Today: Trillion‑Dollar Weight‑Loss Giant Pulls Back After November Surge

Eli Lilly (LLY) Stock Today: Trillion‑Dollar Weight‑Loss Giant Pulls Back After November Surge

Eli Lilly shares closed at $1,075.47 on November 28, down 2.6%, pulling the S&P 500 healthcare sector lower despite gains in the broader market. The stock remains up over 30% for November and more than 40% year-to-date, with a market cap around $1 trillion. JPMorgan raised its price target to $1,150. Recent gains followed strong Q3 earnings and surging sales of Mounjaro and Zepbound.
Eli Lilly (LLY) Stock Dips After Trillion‑Dollar Surge: November 29, 2025 Update for Investors

Eli Lilly (LLY) Stock Dips After Trillion‑Dollar Surge: November 29, 2025 Update for Investors

Eli Lilly shares fell 2.61% to about $1,075.47 on November 29, 2025, continuing a pullback from record highs reached earlier in the month. The company’s market cap stands near $989 billion, with shares still up roughly 43% for the year after a surge fueled by strong Q3 results and demand for obesity drugs. Trading volume was around 2.73 million shares. The stock remains priced at a P/E ratio above 50.
Eli Lilly (LLY) Stock Today, November 28, 2025: Post–$1 Trillion Milestone, Is the Rally Catching Its Breath?

Eli Lilly (LLY) Stock Today, November 28, 2025: Post–$1 Trillion Milestone, Is the Rally Catching Its Breath?

Eli Lilly shares fell about 2.5% to $1,077 in light trading Friday, a week after becoming the first drugmaker to hit a $1 trillion market value. The stock remains up 33% year-to-date and trades near its record high. Mounjaro and Zepbound drove over $10 billion in quarterly sales, more than half of company revenue. Lilly recently reached a deal with the U.S. government to expand access to its obesity drugs.
28 November 2025
Stock Market Today, November 26, 2025: Dow Futures Rise On Fed Rate-Cut Bets As Nvidia, Apple, Bitcoin And Eli Lilly Take Center Stage

Stock Market Today, November 26, 2025: Dow Futures Rise On Fed Rate-Cut Bets As Nvidia, Apple, Bitcoin And Eli Lilly Take Center Stage

U.S. stock futures rose early Wednesday, with Dow, S&P 500, and Nasdaq futures up 0.2%–0.35% as traders bet on a December Fed rate cut. Nvidia and AMD slipped on news of an Alphabet–Meta AI chip partnership. Apple gained after a rebound in China iPhone sales. Eli Lilly hovered near a $1 trillion valuation on strong demand for weight-loss drugs.
Eli Lilly (LLY) Stock Today: $1 Trillion Pharma Giant Extends Rally on Bernstein Upgrade and GLP‑1 Momentum – 25 November 2025

Eli Lilly (LLY) Stock Today: $1 Trillion Pharma Giant Extends Rally on Bernstein Upgrade and GLP‑1 Momentum – 25 November 2025

Eli Lilly shares closed at $1,092.4 on Tuesday, up over 2%, after Bernstein raised its price target to $1,300 citing optimism for the obesity drug orforglipron. The stock’s market value stands near $1 trillion, with shares up more than 50% in three months and trading above the average analyst target. Trading volume was about 1.2 million shares.
Eli Lilly (LLY) Stock Today, November 24, 2025: Trillion‑Dollar Milestone, $1,300 Price Target and New Weight‑Loss Shot Data

Eli Lilly (LLY) Stock Today, November 24, 2025: Trillion‑Dollar Milestone, $1,300 Price Target and New Weight‑Loss Shot Data

Eli Lilly shares traded near $1,070 Monday, up 0.9%, with market cap around $960 billion after briefly topping $1 trillion last week—the first healthcare firm to do so. Bernstein raised its price target to $1,300, citing strong obesity drug prospects. Novo Nordisk’s Alzheimer’s trial failure shifted GLP-1 sentiment. Lilly reported new Phase 2 weight-loss drug data showing up to 20% body-weight reduction.
24 November 2025
Eli Lilly Hits $1 Trillion: Weight‑Loss Drugs Turn a 150‑Year‑Old Pharma Into a Tech‑Sized Giant

Eli Lilly Hits $1 Trillion: Weight‑Loss Drugs Turn a 150‑Year‑Old Pharma Into a Tech‑Sized Giant

Eli Lilly became the first pharmaceutical company to reach a $1 trillion market capitalization, with shares trading near $1,058 on Monday. The surge follows strong demand for its weight-loss and diabetes drugs Mounjaro and Zepbound, both based on tirzepatide. Lilly’s stock has climbed over 35% in 2025 and more than 75% since Zepbound’s late 2023 launch. The company now trades at about 50 times expected earnings.
Eli Lilly (LLY) Stock Today, November 23, 2025: Trillion‑Dollar Milestone, GLP‑1 Price War and Fresh Institutional Buying

Eli Lilly (LLY) Stock Today, November 23, 2025: Trillion‑Dollar Milestone, GLP‑1 Price War and Fresh Institutional Buying

Eli Lilly closed Friday at about $1,060 per share, briefly topping a $1 trillion market cap—the first drugmaker to do so. Institutional filings released Sunday show Coldstream Capital raised its stake by 43.5% in Q2, while Charles Schwab Investment Management increased holdings to 5.36 million shares. LLY is up over 35% year-to-date, driven by demand for its GLP-1 obesity drugs.
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock Today, November 22, 2025: Trillion‑Dollar Milestone, New Board Member and Fresh Access Deals Fuel Momentum

Eli Lilly closed Friday, November 21, 2025, with a market value near $1 trillion, the first drugmaker to reach that mark. Shares ended around $1,060, just below their all-time high. The surge follows strong demand for its obesity and diabetes drugs, which now generate over $10 billion in quarterly sales. Year-to-date, the stock is up about 36%.
Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

US Stock Market Today, November 22, 2025: Wall Street Ends a Wild Week Higher as Fed Cut Bets Rise and AI Rally Shows Cracks

The Dow Jones, S&P 500, and Nasdaq all jumped over 0.9% Friday, November 21, but still closed the week lower, with losses ranging from 1.9% to 2.7%. A shift in Federal Reserve rate-cut expectations fueled the rally after New York Fed President John Williams signaled a possible cut in December. Eli Lilly reached a $1 trillion valuation, the first for a healthcare company. US stock futures rose Friday evening.
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock on November 15, 2025: Pricing Deal, Oral‑Obesity Pill Timeline, Q3 Beat Put Shares Near $1T — Outlook & Risks

Eli Lilly shares traded near $1,025 on Nov. 15, valuing the company just under $1 trillion. The White House announced a deal to lower Zepbound prices and expand public access, while Lilly expects FDA approval of its oral GLP‑1 pill by March 2026. Q3 revenue rose 54% to $17.6 billion. Lilly Endowment filed stock sales around the $1,000 level this month.
15 November 2025
Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals announced partnerships with Eli Lilly and Novo Nordisk to offer official access to Zepbound and Wegovy through new telehealth programs, MangoRx Direct and PeachesRx Direct. Membership costs $99 per month, with GLP‑1 drugs starting at $499 monthly, no insurance required. MGRX shares jumped over 25% pre-market before retreating. The company recently settled a lawsuit with Lilly and reported a $10.3 million net loss.
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk (NVO) Today — Nov. 12, 2025: WeightWatchers to Offer Wegovy Pill, Canada Eyes Ozempic Copies, and the Latest Stock Move

WeightWatchers plans to offer Novo Nordisk’s oral Wegovy in the U.S. after its expected 2026 launch. Sandoz says unbranded Ozempic could reach Canada by June 2026, intensifying price competition. CVS dropped Lilly’s Zepbound from its preferred list, keeping Wegovy, prompting Lilly to move employees off CVS plans. Novo Nordisk shares traded at $49.76 late Wednesday, up slightly.
Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

Stock Market Today (Nov. 11, 2025): Dow Closes at a Record as AI Shares Stumble; FTSE 100 Hits New High on BoE Cut Bets

The Dow Jones closed at a record 47,927.96 on Nov. 11, 2025, up 1.18%, while the Nasdaq fell 0.25% as Nvidia dropped nearly 3% after SoftBank revealed a $5.8 billion stake sale. The S&P 500 edged higher. In Europe, the FTSE 100 hit a record near 9,900, boosted by Vodafone’s first dividend increase in eight years and rising bets on Bank of England rate cuts.
Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly agreed to pay $75 million upfront and over $400 million in milestones for global rights to MeiraGTx’s pediatric blindness gene therapy. The company also announced an AI drug discovery partnership with Insilico Medicine, worth over $100 million in potential payments. Leerink Partners upgraded Lilly shares and raised its price target to $1,104, sending the stock up about 5% intraday.
1 8 9 10 11 12

Stock Market Today

  • Queen Mary Highlights Tasmanian Biodiversity Loss on Royal Visit
    May 23, 2026, 4:39 AM EDT. Queen Mary marked Biodiversity Day by sharing photos from her childhood street in Tasmania, spotlighting the region's rich but vulnerable seaweed forests. These dense underwater forests support hundreds of species but have lost 95% coverage due to ocean warming. The University of Tasmania is actively restoring this ecosystem through innovative projects involving sea urchin management and indigenous collaboration. This local conservation effort, emphasized during Queen Mary's March visit with King Frederik, underscores the global importance of protecting unique coldwater biodiversity. Queen Mary expressed pride in her Tasmanian roots during their first official visit to the area since 2005, highlighting the critical connection between local action and broader environmental benefits.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 23.05.2026

23 May 2026
LIVEMarkets rolling coverageStarted: May 23, 2026, 4:00 AM EDTUpdated: May 23, 2026, 4:40 AM EDT Queen Mary Highlights Tasmanian Biodiversity Loss on Royal Visit May 23, 2026, 4:39 AM EDT. Queen Mary marked Biodiversity Day by sharing photos from her childhood street in Tasmania, spotlighting the region’s rich but vulnerable seaweed forests. These dense underwater forests support hundreds of species but have lost 95% coverage due to ocean warming. The University of Tasmania is actively restoring this ecosystem through innovative projects involving sea urchin management and indigenous collaboration. This local conservation effort, emphasized during Queen Mary’s March visit with King
Dow Hits Record Close; All Eyes Turn to Holiday-Week Trading

Dow Hits Record Close; All Eyes Turn to Holiday-Week Trading

23 May 2026
The Dow closed at a record 50,579.70 on Friday, while the S&P 500 notched its eighth straight weekly gain. After-hours trading saw SPY, QQQ, DIA, and IWM all move lower. U.S. markets will be closed Monday for Memorial Day. Investors await Thursday’s inflation data.
IREN Stock Pauses as Nvidia Rally Cools Before Holiday

IREN Stock Pauses as Nvidia Rally Cools Before Holiday

23 May 2026
IREN shares fell 2.1% to $56.83 Friday, ending a two-day rally but closing the week up 7.4%. The stock’s moves follow a $3.4 billion AI cloud deal with Nvidia and a $3 billion convertible note offering. March-quarter revenue dropped to $144.8 million, with a net loss of $247.8 million. U.S. markets close Monday for Memorial Day; trading resumes Tuesday.
Go toTop